In 2026, her family described changes that felt different from her lifelong intellectual and language baseline. She sometimes forgot her usual seat at the family table or where cups and plates belonged in a familiar kitchen. When she could not retrieve the word "spaghetti," she described it as "the long noodles."
In a caregiver questionnaire, her family described more than isolated naming difficulty. They reported problems with object names and broader sentence, reading, or comprehension tasks. Sometimes she appears still to know the word or meaning even when she cannot produce the exact word. They also reported forgetting familiar object locations, recent events, faces, and appointments; becoming disoriented in new and familiar places; and changes in her ability to complete multistep activities. Her family sees better and worse days, and stress can make the problems more visible.
The 2026 clinical-genetics letter records memory difficulty for approximately two years, especially affecting short-term memory, together with worsening cognitive performance. It also describes some of the newer clinical symptoms as partly progressive. These changes warrant careful follow-up, but the letter does not diagnose dementia or identify a single cause.
Her mother has been clear about the sequence: the cognitive and functional changes began before the severe shoulder pain in spring 2026 and did not become worse because of that shoulder pain. Pain, sleep loss, and hospital stress may still affect performance on a particular day, but they do not account for the reported onset of the newer concerns.
Neuropsychological testing was underway in April 2026. She was in severe pain, sleeping poorly, and under substantial hospital stress on the day her mother described the assessment, all of which are relevant when interpreting that day's performance. A psychiatry referral in June requested assessment for possible early dementia or a neurodegenerative process. Results of these assessments have not yet been reported.
A brain MRI with diffusion imaging and intracranial MRA in April 2026 was limited by movement. As far as it could be assessed, the visible brain structures appeared normal. There was no focal lesion, acute ischemia, hemorrhage, mass, hydrocephalus, relevant arterial stenosis or occlusion, or aneurysm, and no major change from a 2020 MRI was seen. A later genetics letter summarized the scan as unremarkable and unchanged. Because movement limited the MRI, it cannot determine whether the reported everyday changes are progressive, fluctuating, or mixed. A neurologic PET/CT had also been considered earlier in 2026; no completed PET/CT result has been reported.
The March exome-reanalysis laboratory report said that the known ASH1L finding did not explain the dementia-like development. The later clinical geneticist considered it conceivable that the memory impairment could relate to ASH1L, but did not interpret the presentation as a primary neurodegenerative disorder and stated that no increased ASH1L dementia risk has been demonstrated in the limited available data. The relationship between ASH1L and the cognitive changes therefore remains unresolved, underscoring the need to follow her own baseline and function over time.
At present, dementia, primary neurodegeneration, and generalized accelerated aging are not established diagnoses. Any interpretation must use her earlier abilities as the baseline and account for hearing access, sleep, medication, pain, blank episodes, cardiac rhythm, and nutritional or endocrine factors without assuming that any one of them caused the changes.